A partir de cette page vous pouvez :
Retourner au premier écran avec les dernières notices... |
Descripteurs (mots clés)
Thésaurus Mesh
> P > Phentolamine
Phentolamine
A nonselective alpha-adrenergic antagonist. It is used in the treatment of hypertension and hypertensive emergencies, pheochromocytoma, vasospasm of RAYNAUD DISEASE and frostbite, clonidine withdrawal syndrome, impotence, and peripheral vascular disease.
Relation(s)
- voir aussi au terme générique : [Descripteurs (mots clés)] Imidazolés
Ajouter le résultat dans votre panier Affiner la recherche
Etendre la recherche sur niveau(x) vers le bas
Approche pharmacologique de la presbytie [partie I] / Jean-Pierre Lagacé in L'optométriste (UNIQUEMENT ACCESSIBLE EN PDF), vol. 44, 03 (Mai-juin 2022)
[article]
in L'optométriste (UNIQUEMENT ACCESSIBLE EN PDF) > vol. 44, 03 (Mai-juin 2022)
Titre : Approche pharmacologique de la presbytie [partie I] Type de document : article de périodique Auteurs : Jean-Pierre Lagacé Année de publication : 2022 Langues : Français (fre) Descripteurs (mots clés) : [Thésaurus Mesh]:P:Presbytie:Presbytie / thérapie
[Thésaurus Mesh]:P:Presbytie:Presbytie / traitement médicamenteux
[Thésaurus Mesh]Phentolamine
[Thésaurus Mesh]Pilocarpine
[Thésaurus Mesh]Presbytie
[Thésaurus Mesh]Solutions ophtalmiques
[Thésaurus Mesh]Troubles de la visionRésumé : Dans le monde, on compte 1,8 milliard de presbytes, dont 826 millions sont malvoyants en raison d’une correction visuelle inadéquate. Bien que la plupart des Américains aient accès à une correction de la vision de près, nombre d’entre eux ne sont pas satisfaits de leur expérience de la presbytie ou des possibilités de la corriger. Permalink : https://bibliotheque.helb-prigogine.be/opac_css/index.php?lvl=notice_display&id= [article]Exemplaires
Cote Support Localisation Section Disponibilité aucun exemplaire Phentolamine Eye Drops Reverse Pharmacologically Induced Mydriasis in a Randomized Phase 2b Trial / Paul M. Karpecki in OVS : Optometry & Vision Science, vol. 98, 03 (Mars 2021)
[article]
in OVS : Optometry & Vision Science > vol. 98, 03 (Mars 2021)
Titre : Phentolamine Eye Drops Reverse Pharmacologically Induced Mydriasis in a Randomized Phase 2b Trial Type de document : article de périodique Auteurs : Paul M. Karpecki ; Shane A. Foster ; Stephen M. Montaquila ; Shane R. Kannarr ; Charles B. Slonim ; Alan R. Meyer ; Mina P. Sooch ; Reda M. Jaber ; Konstantinos Charizanis ; Jonah E. Yousif ; Seth A. Klapman ; Arin T. Amin ; Marguerite B. McDonald ; Gerald D. Horn ; Eliot S. Lazar ; Jay S. Pepose Année de publication : 2021 Langues : Français (fre) Descripteurs (mots clés) : [Thésaurus Mesh]:M:Mydriase:Mydriase / thérapie
[Thésaurus Mesh]Mydriase
[Thésaurus Mesh]Phentolamine
[Thésaurus Mesh]Solutions ophtalmiquesRésumé : SIGNIFICANCE: After a dilated eye examination, many patients experience symptoms of prolonged light sensitivity, blurred vision, and cycloplegia associated with pharmacological mydriasis. Phentolamine mesylate ophthalmic
solution (PMOS) may expedite the reversal of mydriasis in patients, potentially facilitating return to functional vision and reducing barriers to obtaining dilated eye examinations.
PURPOSE: The protracted reversal time after pharmacologically induced pupil dilation impairs vision. We tested
the hypothesis that PMOS rapidly reduces pupil diameter in this acute indication.
METHODS: In this double-masked placebo-controlled, randomized, two-arm crossover phase 2b trial, we evaluated
the effects of one drop of 1% PMOS applied bilaterally in subjects who had their pupils dilated by one of two common
mydriatic agents: 2.5% phenylephrine or 1% tropicamide. End points included change in pupil diameter, percent
of subjects returning to baseline pupil diameter, and accommodative function at multiple time points.
RESULTS: Thirty-one subjects completed the study (15 dilated with phenylephrine and 16 with tropicamide).
Change in pupil diameter from baseline at 2 hours after maximal dilation with 1% PMOS was −1.69 mm and
was significantly greater in magnitude compared with placebo for every time point beyond 30 minutes (P < .05).
At 2 hours, a greater percentage of study eyes given 1% PMOS returned to baseline pupil diameter compared with
placebo (29 vs. 13%, P = .03), which was this also seen at 4 hours (P < .001). More subjects treated with PMOS in
the tropicamide subgroup had at least one eye returning to baseline accommodative amplitude at 2 hours (63 vs.
38%, P = .01). There were no severe adverse events, with only mild to moderate conjunctival hyperemia that resolved in most patients by 6 hours.
CONCLUSIONS: Phentolamine mesylate ophthalmic solution at 1% reversed medically induced pupil dilation
more rapidly than placebo treatment regardless of which mydriatic was used (adrenergic agonists and cholinergic
blockers) with a tolerable safety profile.Note de contenu :
Permalink : https://bibliotheque.helb-prigogine.be/opac_css/index.php?lvl=notice_display&id= [article]Exemplaires
Cote Support Localisation Section Disponibilité aucun exemplaire